ReviewNeuroprotection (Chichester, England)2026
Cerebral in situ ischemic postconditioning: From bench to bedside and beyond.
Review in Neuroprotection (Chichester, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ischemic postconditioning (IPostC) has emerged as a promising therapeutic strategy for mitigating ischemia-reperfusion injury in ischemic tissues. However, its neuroprotective potential following thrombectomy in acute ischemic stroke (AIS) remains underexplored in clinical settings. To address this gap, we conducted a review to evaluate the feasibility, clinical relevance, and safety of IPostC in AIS patients. This review is structured in four parts. First, we assess the translational success of IPostC from preclinical research to clinical applications in non-neurological organs. Second, we examine data from animal models of cerebral ischemia, including rodents and canines, to evaluate the potential applicability of IPostC in the brain. Based on an integrated synthesis of these findings, we argue that clinical translation of IPostC for stroke treatment is both feasible and potentially beneficial. Furthermore, by incorporating insights from related endovascular interventions, we refine the proposed IPostC protocol to support safer and more effective clinical implementation. Finally, we introduce a novel in situ neurointerventional IPostC technique and discuss its potential clinical implications.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.